Marengo Therapeutics presented interim Phase 2 results from the STARt-002 trial combining invikafusp alfa, a selective T-cell agonist, with sacituzumab govitecan in metastatic triple-negative and HR-positive/HER2-negative breast cancer. The trial showed reductions in tumor lesions in 71% of patients and confirmed complete responses in both cancer subtypes, including durable responses beyond one year. This novel immune therapy combo demonstrated manageable safety and potential to improve outcomes in patients with limited treatment options. Further development is planned to expand its use across broader cancer populations.
Marengo Therapeutics' interim Phase 2 results provide context for readers interested in innovative cancer therapies. For readers following the health sector, here is Pluang's market snapshot as of Nov 09, 2026 18:41 WIB: out of 150 priced US health stocks, 108 rose and 26 fell. Notable movers include TG Therapeutics Inc (TGTX) at USD 63.00 with a 1-day change of +5.31%, Guardant Health Inc. (GH) at USD 157.76 with +4.57%, and ClearPoint Neuro Inc (CLPT) at USD 8.99 with +4.53%.
Holzer & Holzer, LLC announced deadlines for investors to seek lead plaintiff status in shareholder class action lawsuits against The Ensign Group, Netcapital Inc., and Webull Corporation. These lawsuits allege misleading statements and failure to di...
Octave Intelligence plc has introduced Octave Attune Facilities, a cloud-based software solution designed to help organizations manage multiple sites with AI-powered tools. This platform integrates building, space, maintenance, and operational data t...
ITT Inc. reported a strong third quarter with revenue up 44% to over $1.40 billion and adjusted earnings rising 20% to $2.26 per share, driven by the SPX FLOW acquisition and 8% organic growth. Orders surged 58%, supported by aerospace, defense, and ...
Credit Agricole Toulouse 31 disclosed its weekly transactions involving the buyback of its cooperative investment certificates (CCI) from November 2 to November 6, 2026. The bank repurchased varying volumes daily, with prices ranging around 98.82 to ...
Heineken N.V. has repurchased a total of 9,814,488 shares under the second tranche of its €1.5 billion share buyback program, spending approximately €704 million up to November 6, 2026. This tranche is part of a larger plan announced in February 2026...
